Skip to main content

Early Detection

Advances research to determine the effectiveness and clinical impact – harms and benefits – of cancer early detection technologies and practices, including imaging and molecular biomarker approaches. Fosters technological development, statistical modeling, and dissemination of scientific findings to promote early cancer detection practices.

On This Page

All Heading 2s will automatically be pulled in to this list.
Do not edit the content on this template.

Major Programs

Resources

Cancer Data Access System (CDAS)

Staff List

Grid View

Photo	Name, Email, Phone	Room	Group(s)/Office
	LeeVan, Elyse, M.D., M.P.H. elyse.leevan@nih.gov 240-276-7314	5E110	Program Officer \| Early Detection
	McCarty, Larae larae.mccarty@nih.gov 240-276-5777	5E322	Program Specialist \| Community Oncology and Prevention Trials Early Detection
	Miller, Eric, Ph.D. eric.miller2@nih.gov 240-276-5336	5E212	Program Officer \| Early Detection
	Ong, Mary Jane maryjane.ong@nih.gov 240-858-3296	5E120	Nurse Consultant \| Early Detection
	Pinsky, Paul, Ph.D. paul.pinsky@nih.gov 240-276-7014	5E108	Chief \| Early Detection
	Saxena, Neeraj, Ph.D. neeraj.saxena@nih.gov 240-276-6302	5E218	Program Officer \| Early Detection
	Zhu, Claire, Ph.D. claire.zhu@nih.gov 240-276-7013	5E106	Program Officer \| Early Detection

Grants

PI Name Sort descending	PI Organization	Title	Grant Number	Program Official
Skates, Steven J	Massachusetts General Hospital United States	Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls	5U01CA260758-05	Claire Zhu, Ph.D.
Skubitz, Amy Patrice	University Of Minnesota United States	A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection	5R01CA262153-05	Christos Patriotis, Ph.D., M.Sc.
Slager, Susan L	Mayo Clinic Rochester United States	The genetic and epigenetic etiology of progression from the precursor state to chronic lymphocytic leukemia (CLL)	4R01CA258465-04	Nicholas Hodges, Ph.D.
Smith, Ellen Mary Lavoie	University Of Alabama At Birmingham United States	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study	5R01CA235726-07	Brennan Streck, Ph.D., RN, M.P.H.
Smith, Jennifer Susan	Univ Of North Carolina Chapel Hill United States	UNC CASCADE Network Research Base	5UG1CA275403-04	Maria Silvina Frech, Ph.D., M.S.
Sohl, Stephanie Jean	Wake Forest University Health Sciences United States	REmotely-delivered Supportive Programs for Improving surgical pain and disTrEss (RESPITE)	5R01CA266995-04	Goli Samimi, Ph.D., M.P.H.
Somers, Tamara J	Duke University United States	A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial	5R01CA237892-05	Brennan Streck, Ph.D., RN, M.P.H.
Song, Ming	University Of Louisville United States	Dietary fructose and NASH/HCC progression	5R21CA290420-02	Amit Kumar, Ph.D.
Sorror, Mohamed	Fred Hutchinson Cancer Center United States	Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality	5R01CA227092-06	Marjorie Perloff, M.D.
Spector, Tim	King'S College London United States	PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors	1OT2CA297289-01	Asad Umar, D.V.M., Ph.D.
Spiegel, Brennan	Cedars-Sinai Medical Center United States	Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	5R01CA252211-05	Rachel Altshuler, Ph.D.
Stachler, Matthew D	University Of California, San Francisco United States	Optimization and validation of a biomarker panel for risk stratification in Barrett's esophagus	3R37CA269649-03S1	Matthew Young, Ph.D.
Staff, Nathan P	Mayo Clinic Rochester United States	Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity	5R01CA275870-03	Rachel Altshuler, Ph.D.
Stolley, Melinda R	Medical College Of Wisconsin United States	Every Day Counts: A lifestyle program for women metastatic breast cancer	5R01CA258759-04	Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Storz, Peter	Mayo Clinic Jacksonville United States	Deiminated molecules as markers for developing pancreatic cancer - A1	5R21CA279916-02	Matthew Young, Ph.D.